← Back to Search

3D-MPUS for Liver Cancer (3DMPUS Trial)

N/A
Waitlist Available
Led By Ahmed El Kaffas, PhD
Research Sponsored by Stanford University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline and 3 months post treatment
Awards & highlights

3DMPUS Trial Summary

This trial studies an inexpensive & safe method that may provide info about patient treatment response for liver tumors.

Who is the study for?
This trial is for adults over 18 with liver tumors who are starting a new treatment. They must have at least one tumor between 1cm and 14cm, be willing to follow the study rules, and able to give informed consent. It's not for those with severe allergies to contrast media used in ultrasounds or CT scans, pregnant or breastfeeding women, people with certain heart conditions, kidney issues (creatinine >1.5mg/dl), or uncontrolled high blood pressure.Check my eligibility
What is being tested?
The trial is testing how well a new imaging technique called 3D multi-parametric ultrasound (3D-MPUS) helps in making treatment decisions for liver cancer patients. This method could provide additional functional information about the tumor during therapy that current methods don't offer.See study design
What are the potential side effects?
There may be minimal side effects from the use of ultrasound contrast agents during the imaging process; however, individuals prone to severe reactions to such contrasts are excluded from this study.

3DMPUS Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline and 3 months post treatment
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline and 3 months post treatment for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Diagnostic yield of the 3D-MPUS data acquisition
Secondary outcome measures
Inter-reader agreement for 3D-MPUS measurements at first scan
Relationship between baseline and one-month 3D-MPUS measurements and treatment response after three-months

3DMPUS Trial Design

1Treatment groups
Experimental Treatment
Group I: 3-dimensional multi-parametric ultrasound imaging (3D-MPUS)Experimental Treatment1 Intervention
Participants will receive sulfur hexafluoride IV and undergo 3D-MPUS imaging over 20 minutes.

Find a Location

Who is running the clinical trial?

Stanford UniversityLead Sponsor
2,387 Previous Clinical Trials
17,333,970 Total Patients Enrolled
10 Trials studying Liver Cancer
1,008 Patients Enrolled for Liver Cancer
National Cancer Institute (NCI)NIH
13,657 Previous Clinical Trials
40,933,587 Total Patients Enrolled
104 Trials studying Liver Cancer
26,668 Patients Enrolled for Liver Cancer
Ahmed El Kaffas, PhDPrincipal InvestigatorStanford University

Media Library

3-dimensional multi-parametric ultrasound imaging (3D-MPUS) Clinical Trial Eligibility Overview. Trial Name: NCT05705219 — N/A
Liver Cancer Research Study Groups: 3-dimensional multi-parametric ultrasound imaging (3D-MPUS)
Liver Cancer Clinical Trial 2023: 3-dimensional multi-parametric ultrasound imaging (3D-MPUS) Highlights & Side Effects. Trial Name: NCT05705219 — N/A
3-dimensional multi-parametric ultrasound imaging (3D-MPUS) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05705219 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is this experiment accepting new participants?

"According to clinicaltrials.gov, this research is not presently enrolling patients; it was initially advertised on March 1st 2023 and last updated on January 18th 2023. However, there are 602 other trials actively seeking participants at the moment."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Development of 3DMPUS as a Decision Support Tool for Patients With Liver Tumors Undergoing Therapy
Ahmed Nagy El Kaffas 2023. "Development of 3DMPUS as a Decision Support Tool for Patients With Liver Tumors Undergoing Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05705219.
~53 spots leftby Dec 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top